These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22537887)

  • 1. Tumor heterogeneity and its implication for drug delivery.
    Denison TA; Bae YH
    J Control Release; 2012 Dec; 164(2):187-91. PubMed ID: 22537887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development.
    Dzobo K; Senthebane DA; Thomford NE; Rowe A; Dandara C; Parker MI
    OMICS; 2018 Jan; 22(1):17-34. PubMed ID: 29356626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems.
    Dianat-Moghadam H; Heidarifard M; Jahanban-Esfahlan R; Panahi Y; Hamishehkar H; Pouremamali F; Rahbarghazi R; Nouri M
    J Control Release; 2018 Oct; 288():62-83. PubMed ID: 30184466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics.
    Lin Q; Yun Z
    Cancer Biol Ther; 2010 Jun; 9(12):949-56. PubMed ID: 20581454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.
    Poste G
    Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mesenchymal tumor microenvironment: a drug-resistant niche.
    Cukierman E; Bassi DE
    Cell Adh Migr; 2012; 6(3):285-96. PubMed ID: 22568991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tumor microenvironment to curb chemoresistance via novel drug delivery strategies.
    Bhavsar C; Momin M; Khan T; Omri A
    Expert Opin Drug Deliv; 2018 Jul; 15(7):641-663. PubMed ID: 29301448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach.
    Malhi S; Gu X
    Expert Opin Drug Deliv; 2015 Jul; 12(7):1177-201. PubMed ID: 25601619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The development of novel tumor targeting delivery strategy].
    Gao HL; Jiang XG
    Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response.
    Noman MZ; Messai Y; Carré T; Akalay I; Méron M; Janji B; Hasmim M; Chouaib S
    Crit Rev Immunol; 2011; 31(5):357-77. PubMed ID: 22142164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving Strategies for Therapeutically Targeting Cancer Stem Cells.
    Talukdar S; Emdad L; Das SK; Sarkar D; Fisher PB
    Adv Cancer Res; 2016; 131():159-91. PubMed ID: 27451127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.
    Yang Q; Parker CL; McCallen JD; Lai SK
    J Control Release; 2015 Dec; 220(Pt B):715-26. PubMed ID: 26407672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting.
    Persano L; Rampazzo E; Basso G; Viola G
    Biochem Pharmacol; 2013 Mar; 85(5):612-622. PubMed ID: 23063412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: Targeting tumor microenvironment heterogeneity.
    Hida K; Ishii G
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):139. PubMed ID: 27018072
    [No Abstract]   [Full Text] [Related]  

  • 18. Differentiation and transdifferentiation potentials of cancer stem cells.
    Huang Z; Wu T; Liu AY; Ouyang G
    Oncotarget; 2015 Nov; 6(37):39550-63. PubMed ID: 26474460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy.
    Muntimadugu E; Kommineni N; Khan W
    Pharmacol Res; 2017 Dec; 126():109-122. PubMed ID: 28511988
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.